These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34806209)

  • 1. A brief screening tool for depression in psoriasis patients: The Two Questions Test in clinical practice.
    Hölsken S; Krefting F; Schneider L; Benson S; Schedlowski M; Sondermann W
    J Dermatol; 2022 Mar; 49(3):341-348. PubMed ID: 34806209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for depression in psoriasis patients during a dermatological consultation: A first step towards treatment.
    Kromer C; Mohr J; Celis D; Poortinga S; Gerdes S; Mössner R; Wilsmann-Theis D
    J Dtsch Dermatol Ges; 2021 Oct; 19(10):1451-1461. PubMed ID: 34467650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity.
    Esposito M; Giunta A; Nanni RC; Criscuolo S; Manfreda V; Del Duca E; Bianchi L; Troisi A
    Arch Dermatol Res; 2021 Aug; 313(6):431-437. PubMed ID: 32776228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stigmatization feelings and depression symptoms in psoriasis patients.
    Zięciak T; Rzepa T; Król J; Żaba R
    Psychiatr Pol; 2017 Dec; 51(6):1153-1163. PubMed ID: 29432510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and
    Kim SJ; Park MY; Pak K; Han J; Kim GW; Kim HS; Ko HC; Kim MB; Kim BS
    J Dermatolog Treat; 2018 Dec; 29(8):761-768. PubMed ID: 29658378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
    J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
    JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression and sleep quality in psoriatic patients: impact of psoriasis severity.
    Luca M; Musumeci ML; D'Agata E; Micali G
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):102-104. PubMed ID: 31852324
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
    Griffiths CEM; Fava M; Miller AH; Russell J; Ball SG; Xu W; Acharya N; Rapaport MH
    Psychother Psychosom; 2017; 86(5):260-267. PubMed ID: 28903122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study.
    Martínez-Ortega JM; Nogueras P; Muñoz-Negro JE; Gutiérrez-Rojas L; González-Domenech P; Gurpegui M
    J Psychosom Res; 2019 Sep; 124():109780. PubMed ID: 31443809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between symptoms and patient characteristics among psoriasis patients.
    Bilac C; Ermertcan AT; Bilac DB; Deveci A; Horasan GD
    Indian J Dermatol Venereol Leprol; 2009; 75(5):551. PubMed ID: 19736461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep disturbance in psoriasis: a case-controlled study.
    Jensen P; Zachariae C; Skov L; Zachariae R
    Br J Dermatol; 2018 Dec; 179(6):1376-1384. PubMed ID: 29704428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two questions may be enough - screening for depression in patients with psoriasis: a multicenter study.
    Gerdes S; Wilsmann-Theis D; Celis D; Kromer C; Mössner R
    J Dtsch Dermatol Ges; 2020 Oct; 18(10):1115-1125. PubMed ID: 32945601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suicide risk and depression in patients with psoriasis.
    Bardazzi F; Bonci C; Sacchelli L; DI Altobrando A; Iommi M; Rucci P; Sacchelli P; Berardi D; Patrizi A; Tengattini V
    Ital J Dermatol Venerol; 2022 Dec; 157(6):497-501. PubMed ID: 36651203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
    Tang MM; Chang CC; Chan LC; Heng A
    Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.